Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 21:17:1635.
doi: 10.3332/ecancer.2023.1635. eCollection 2023.

Real-world data on triple-negative breast cancer in Latin America and the Caribbean

Katsuki Arima Tiscoski  1   2 , Juliana Giacomazzi  3   4 , Matheus Soares Rocha  3   5 , Gustavo Gössling  3   6 , Gustavo Werutsky  3   7
Affiliations
Review

Real-world data on triple-negative breast cancer in Latin America and the Caribbean

Katsuki Arima Tiscoski et al. Ecancermedicalscience. .

Abstract

Breast cancer (BC) is the most prevalent cancer in women in Latin America and the Caribbean. We compiled real-world data (RWD) on the epidemiology, diagnosis, treatment, and patient outcomes of triple-negative breast cancer (TNBC), addressing the main barriers to optimal care in Latin America. The prevalence of TNBC varies between 11% and 38.5% of all BC cases diagnosed in the region, and TNBC primarily affects young patients. Delays in BC diagnosis, with consequent advanced disease stages and barriers to access efficient therapies, particularly due to high costs, negatively impact patient outcomes. Cancer clinical trials are an opportunity to access standard and novel therapies for patients with this aggressive BC subtype and thus must be prioritised. Finally, generating RWD and cost-effectiveness studies in a region with limited resources is critical for decision-makers to define the incorporation of new technologies for the treatment of BC.

Keywords: Caribbean Region; Latin America; breast neoplasms; triple negative breast neoplasms.

PubMed Disclaimer

Conflict of interest statement

JG reports grants from Roche. GW reports grants or contracts from Novartis, Roche/Genentech, AstraZeneca/MedImmune, Lilly, GlaxoSmithKline, Novartis, Pfizer, Bristol-Myers Squibb Brazil, MSD, Merck, Bayer, Janssen, BMS, Astellas, Libbs, Takeda, Celgene, GSK; consulting fees from Merck; payment or honoraria for lectures from Pfizer, AstraZeneca/MedImmune, Libbs, and Merck. The other authors declare no conflict of interest.

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Piñeros M, Laversanne M, Barrios E, et al. An updated profile of the cancer burden, patterns and trends in Latin America and the Caribbean. Lancet Reg Health Am. 2022;13 - PMC - PubMed
    1. Cazap E. Breast cancer in Latin America: a map of the disease in the region. Am Soc Clin Oncol Educ Book. 2018;38:451–456. doi: 10.1200/EDBK_201315. - DOI - PubMed
    1. Goss PE, Lee BL, Badovinac-Crnjevic T, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013;14(5):391–436. doi: 10.1016/S1470-2045(13)70048-2. [Internet] - DOI - PubMed
    1. Hiatt RA, Brody JG. Environmental determinants of breast cancer. Annu Rev Public Health. 2018;39(1):113–133. doi: 10.1146/annurev-publhealth-040617-014101. [Internet] - DOI - PubMed

LinkOut - more resources